TY - JOUR
T1 - An Eluate of the Medicinal Plant Garcinia kola Displays Strong Antidiabetic and Neuroprotective Properties in Streptozotocin-Induced Diabetic Mice
AU - Seke Etet, Paul F.
AU - Hamza, Muaawia A.
AU - El-Tahir, Ahmed
AU - Vecchio, Lorella
AU - Osman, Sayed Y.
AU - Satti, Gwiria M.H.
AU - Ismail, Mohamed H.A.
AU - Farahna, Mohammed
AU - Njamnshi, Alfred K.
AU - Adem, Abdu
N1 - Publisher Copyright:
© 2022 Paul F. Seke Etet et al.
PY - 2022
Y1 - 2022
N2 - Scope. The neuroprotective properties of the antidiabetic plant Garcinia kola have been reported. Here, we performed a motor sign prevention-guided fractionation of G. kola extract in diabetic mice to unravel the components of the most active subfraction, given the potential for the development of drugs with antidiabetic and neuroprotective properties. Materials and Methods. G. kola methanolic extract was fractionated using increasingly polar solvents. Fractions were administered to streptozotocin (STZ)-induced diabetic mice until marked motor signs developed in diabetic controls. Fine motor skills indicators were measured in the horizontal grid test (HGT) to confirm the prevention of motor disorders in treated animals. Column chromatography was used to separate the most active fraction, and subfractions were tested in turn in the HGT. Gas chromatography-mass spectrometry (GC-MS) technique was used to assess the components of the most active subfraction. Results. Treatment with ethyl acetate fraction and its fifth eluate (F5) preserved fine motor skills and improved the body weight and blood glucose level. At dose 1.71 mg/kg, F5 kept most parameters comparable to the nondiabetic vehicle group values. GC-MS chromatographic analysis of F5 revealed 36 compounds, the most abundantly expressed (41.8%) being the β-lactam molecules N-ethyl-2-carbethoxyazetidine (17.8%), N,N-dimethylethanolamine (15%), and isoniacinamide (9%). Conclusions. Our results suggest that subfraction F5 of G. kola extract prevented the development of motor signs and improved disease profile in an STZ-induced mouse model of diabetic encephalopathy. Antidiabetic activity of β-lactam molecules accounted at least partly for these effects.
AB - Scope. The neuroprotective properties of the antidiabetic plant Garcinia kola have been reported. Here, we performed a motor sign prevention-guided fractionation of G. kola extract in diabetic mice to unravel the components of the most active subfraction, given the potential for the development of drugs with antidiabetic and neuroprotective properties. Materials and Methods. G. kola methanolic extract was fractionated using increasingly polar solvents. Fractions were administered to streptozotocin (STZ)-induced diabetic mice until marked motor signs developed in diabetic controls. Fine motor skills indicators were measured in the horizontal grid test (HGT) to confirm the prevention of motor disorders in treated animals. Column chromatography was used to separate the most active fraction, and subfractions were tested in turn in the HGT. Gas chromatography-mass spectrometry (GC-MS) technique was used to assess the components of the most active subfraction. Results. Treatment with ethyl acetate fraction and its fifth eluate (F5) preserved fine motor skills and improved the body weight and blood glucose level. At dose 1.71 mg/kg, F5 kept most parameters comparable to the nondiabetic vehicle group values. GC-MS chromatographic analysis of F5 revealed 36 compounds, the most abundantly expressed (41.8%) being the β-lactam molecules N-ethyl-2-carbethoxyazetidine (17.8%), N,N-dimethylethanolamine (15%), and isoniacinamide (9%). Conclusions. Our results suggest that subfraction F5 of G. kola extract prevented the development of motor signs and improved disease profile in an STZ-induced mouse model of diabetic encephalopathy. Antidiabetic activity of β-lactam molecules accounted at least partly for these effects.
UR - http://www.scopus.com/inward/record.url?scp=85128346219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128346219&partnerID=8YFLogxK
U2 - 10.1155/2022/8708961
DO - 10.1155/2022/8708961
M3 - Article
AN - SCOPUS:85128346219
SN - 1741-427X
VL - 2022
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
M1 - 8708961
ER -